Non-canonical mTORC1-TFEB activation promotes hepatocyte plasticity and high-grade malignancy in hepatocellular carcinoma.

Hepatocellular carcinoma (HCC) is heterogeneous, and hepatocyte plasticity is linked to poorer patient outcomes. A subset of human HCC harboring Tuberous Sclerosis Complex 1 (TSC1) mutations exhibits more aggressive behavior. TFEB is a master regulator of lysosomal biogenesis and cell fate. Loss of hepatic Tsc1 led to increased phosphorylation of S6 and 4EBP1, with paradoxical increases in TFEB nuclear translocation and activation.

Read the full abstract →

Zhang, C., et al. (2026). Non-canonical mTORC1-TFEB activation promotes hepatocyte plasticity and high-grade malignancy in hepatocellular carcinoma. The Journal of clinical investigation. https://doi.org/10.1172/JCI206334

@article{ZHANG2026,
  author       = {Zhang, C. and Chao, X. and Williams, S. N. and Wei, X. and DiGirolamo, A. and others},
  title        = {{Non-canonical mTORC1-TFEB activation promotes hepatocyte plasticity and high-grade malignancy in hepatocellular carcinoma}},
  journal      = {The Journal of clinical investigation},
  year         = {2026},
  doi          = {10.1172/JCI206334},
}

Cite this Atlas record

The record is the Atlas's own work — the evidence label, the extracted findings and the links. It is cited as part of the dataset, not as the paper.

Barton, O. (2026). Oliver's mTOR Atlas (record ZHANG2026) [Data set]. https://mtor-atlas.org/study/ZHANG2026/ · Dataset DOI 10.5281/zenodo.22059963

@misc{atlas_ZHANG2026,
  author       = {Barton, Oliver},
  title        = {{Oliver's mTOR Atlas}, record ZHANG2026},
  howpublished = {Data set},
  year         = {2026},
  url          = {https://mtor-atlas.org/study/ZHANG2026/},
  doi          = {10.5281/zenodo.22059963}
}